Bicocca Open Archive

Logo unimib boa
BONFANTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 22.423
NA - Nord America 22.324
EU - Europa 14.193
SA - Sud America 3.310
AF - Africa 505
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 6
Totale 62.797
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.896
SG - Singapore 7.630
VN - Vietnam 5.531
IT - Italia 5.489
HK - Hong Kong 2.952
CN - Cina 2.835
BR - Brasile 2.495
RU - Federazione Russa 2.129
DE - Germania 1.714
SE - Svezia 1.165
CA - Canada 1.082
IE - Irlanda 964
BD - Bangladesh 688
FR - Francia 558
GB - Regno Unito 535
ID - Indonesia 494
IN - India 493
KR - Corea 341
FI - Finlandia 329
AR - Argentina 310
NL - Olanda 279
IQ - Iraq 222
AT - Austria 211
MX - Messico 204
TR - Turchia 187
UA - Ucraina 178
ZA - Sudafrica 161
JP - Giappone 148
PK - Pakistan 145
ES - Italia 141
EC - Ecuador 126
PH - Filippine 120
PL - Polonia 119
SA - Arabia Saudita 93
CO - Colombia 88
UZ - Uzbekistan 77
VE - Venezuela 72
MY - Malesia 71
MA - Marocco 66
CH - Svizzera 62
CL - Cile 62
PY - Paraguay 60
RO - Romania 60
KE - Kenya 58
AE - Emirati Arabi Uniti 49
JO - Giordania 40
LT - Lituania 37
TH - Thailandia 37
EG - Egitto 36
KZ - Kazakistan 35
TN - Tunisia 32
PE - Perù 31
NP - Nepal 30
UY - Uruguay 30
BE - Belgio 29
BO - Bolivia 28
CZ - Repubblica Ceca 28
AU - Australia 27
DZ - Algeria 27
ET - Etiopia 27
OM - Oman 27
PS - Palestinian Territory 27
JM - Giamaica 25
CR - Costa Rica 24
AL - Albania 22
GR - Grecia 20
IR - Iran 20
IL - Israele 17
BG - Bulgaria 16
HN - Honduras 16
NG - Nigeria 15
TW - Taiwan 15
AZ - Azerbaigian 14
LB - Libano 14
SN - Senegal 14
GT - Guatemala 13
PA - Panama 13
PT - Portogallo 13
TT - Trinidad e Tobago 12
DK - Danimarca 11
HU - Ungheria 11
UG - Uganda 11
BY - Bielorussia 10
KG - Kirghizistan 10
SY - Repubblica araba siriana 10
BH - Bahrain 9
DO - Repubblica Dominicana 9
EE - Estonia 8
MD - Moldavia 8
RS - Serbia 8
NZ - Nuova Zelanda 7
SK - Slovacchia (Repubblica Slovacca) 7
AM - Armenia 6
AO - Angola 6
GE - Georgia 6
GH - Ghana 6
HR - Croazia 6
MU - Mauritius 6
NI - Nicaragua 6
NO - Norvegia 6
Totale 62.667
Salva come PNG Salva come JPEG
Città #
Singapore 3.987
Hong Kong 2.697
Ann Arbor 2.463
Ashburn 1.971
San Jose 1.687
Ho Chi Minh City 1.636
Milan 1.494
Hanoi 1.391
Frankfurt am Main 1.253
Dublin 933
New York 899
Dallas 867
Toronto 819
Fairfield 781
Chandler 748
Hefei 691
Santa Clara 689
Los Angeles 627
Chicago 625
Wilmington 431
Houston 415
Rome 407
Woodbridge 406
The Dalles 398
Princeton 391
Jakarta 388
Beijing 358
Seoul 327
Seattle 324
Lauterbourg 310
Buffalo 279
Council Bluffs 273
Cambridge 225
Moscow 223
São Paulo 212
Altamura 206
Da Nang 191
Haiphong 182
Helsinki 180
Lawrence 179
Boardman 152
Nuremberg 140
London 138
San Diego 124
Shanghai 119
Biên Hòa 115
Tokyo 115
Vienna 112
Dong Ket 109
Hải Dương 109
Munich 104
Orem 99
Ha Long 93
Montreal 92
Quận Bình Thạnh 92
Rio de Janeiro 92
Warsaw 90
Guangzhou 89
Johannesburg 89
Lappeenranta 88
Jacksonville 87
Naples 85
Turin 85
Atlanta 84
Ninh Bình 79
Baghdad 78
Can Tho 78
Thái Nguyên 74
Brooklyn 73
Tashkent 73
Denver 69
Vũng Tàu 69
Chennai 64
Figino 64
Kent 63
Amsterdam 62
Phoenix 62
Andover 61
Bologna 61
Salt Lake City 58
Bắc Ninh 57
Stockholm 56
Dearborn 54
Mexico City 53
Poplar 53
Pune 52
Palermo 51
San Francisco 50
Belo Horizonte 49
Nairobi 48
Zurich 48
Brasília 47
Monza 47
Boston 46
Dhaka 46
Florence 46
Quito 45
Falls Church 44
Lahore 44
Quận Một 44
Totale 37.133
Salva come PNG Salva come JPEG
Nome #
PRESENTAZIONE DEL VADEMECUM DI SIMIT-LOMBARDIA, PER LE VACCINAZIONI DELL’ADULTO A RISCHIO PER CONDIZIONE O PATOLOGIA 719
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 573
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 568
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study 526
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels 509
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 487
Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort 465
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: A randomized multicentric study 445
Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort 444
Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure 405
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 397
Colistin-resistant Acinetobacter baumanii: a case series. 396
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 396
A second update on mapping the human genetic architecture of COVID-19 385
L’esposizione a Rilpivirina rappresenta un fattore di rischio per la progressione della steatosi epatica nelle persone con infezione da HIV. 373
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 368
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 365
Mapping the human genetic architecture of COVID-19 364
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 352
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 350
Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals 344
An immune-based biomarker signature is associated with mortality in COVID-19 patients 341
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 332
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 329
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 328
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy 324
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study 323
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 319
Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status 318
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 316
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 314
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 313
Hospital-Acquired Infections in Critically Ill Patients With COVID-19 312
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view 310
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 306
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 305
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 303
High rates of 30-day mortality in patients with cirrhosis and COVID-19 303
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 297
Association Between Sex Hormone Levels and Clinical Outcomes in Patients With COVID-19 Admitted to Hospital: An Observational, Retrospective, Cohort Study 295
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 295
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 294
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 289
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare 286
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 280
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 278
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 277
Delirium in Patients with SARS‐CoV‐2 Infection: A Multicenter Study 273
Alternative pre-analytical strategies for SARS CoV 2 RNA detection 273
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 272
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 270
RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies 270
Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study 270
A multidisciplinary approach to screen the post-COVID-19 conditions 268
Ceftazidime-avibactam plus aztreonam versus cefiderocol in the treatment of infections caused by Metallo-β lactamase-Producing Microorganisms: real-word data from the Italian cohort SUSANA 262
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 258
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 258
Weight gain: A possible side effect of all antiretrovirals 256
Atrial Fibrillation Incidence in SARS-COV-2 Infected Patients: Predictors and Relationship with in-Hospital Mortality 254
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 251
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 250
Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti? 249
Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment? 248
Insights on HIV infection, some reflecting after eight years of the Journal. 247
HIV and metabolic syndrome - A comparison with the general population 247
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 247
Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy 246
People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they? 243
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 243
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 242
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 240
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 239
The effect of frailty on in-hospital and medium-term mortality of patients with COronaVIrus Disease-19: the FRACOVID study 238
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 237
Incident Atrial Fibrillation and In-Hospital Mortality in SARS-CoV-2 Patients 233
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections 232
Pillars of long-term antiretroviral therapy success 230
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering 228
Ruolo delle strutture ambulatoriali extra-ospedaliere per pazienti con COVID-19: l’esperienza dell’Hotspot COVID di Monza. Role of outpatient facilities for patients with COVID-19: the experience of the COVID Hotspot in Monza. 227
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) 227
One-year survival and Quality of Life of first wave COVID-19 invasively ventilated patients in Lombardy, Italy 226
Awake Prone Positioning in Adults With COVID-19 An Individual Participant Data Meta-Analysis 225
Multiple concomitanti infezioni opportunistiche e linfomi aggressivi in una persona con HIV/AIDS che non assumeva la terapia ant 224
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 223
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 222
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 221
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 218
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 217
Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection 217
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 215
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 213
Symptom profile, case and symptom clustering, clinical and demographic characteristics of a multicentre cohort of 1297 patients evaluated for Long-COVID 213
Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024 212
Symptomatic neurocognitive impairmentassociated to CNS viral escape in an HIV-1 infected patient: a case report. 211
Beware of biases in observational studies on anti-spike monoclonal antibodies 211
Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients. 207
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 207
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort 206
Being a Doctor Will Never Be the Same After the COVID-19 Pandemic 206
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study 206
Totale 29.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 212.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 212.291
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.857 306 319 311 238 160 207 117 201 169 124 194 511
2022/20234.492 587 1.070 440 387 359 707 98 236 290 71 136 111
2023/20243.837 150 117 223 136 475 923 622 127 358 147 80 479
2024/202513.132 646 1.407 679 529 847 706 757 331 1.009 1.747 1.507 2.967
2025/202634.103 4.886 3.127 2.614 3.311 3.157 1.532 4.070 1.480 2.081 2.635 2.197 3.013
2026/2027345 345 0 0 0 0 0 0 0 0 0 0 0
Totale 64.028